114 related articles for article (PubMed ID: 12735660)
21. Onset and duration of action of single doses of formoterol inhaled via Turbuhaler.
Ringdal N; Derom E; Wåhlin-Boll E; Pauwels R
Respir Med; 1998 Aug; 92(8):1017-21. PubMed ID: 9893769
[TBL] [Abstract][Full Text] [Related]
22. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
23. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate.
Mahler DA; Waterman LA; Ward J; Gifford AH
J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):103-9. PubMed ID: 23745526
[TBL] [Abstract][Full Text] [Related]
24. Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study.
Wadbo M; Löfdahl CG; Larsson K; Skoogh BE; Tornling G; Arweström E; Bengtsson T; Ström K;
Eur Respir J; 2002 Nov; 20(5):1138-46. PubMed ID: 12449166
[TBL] [Abstract][Full Text] [Related]
25. Tolerability to high doses of formoterol and terbutaline via Turbuhaler for 3 days in stable asthmatic patients.
Tötterman KJ; Huhti L; Sutinen E; Backman R; Pietinalho A; Falck M; Larsson P; Selroos O
Eur Respir J; 1998 Sep; 12(3):573-9. PubMed ID: 9762782
[TBL] [Abstract][Full Text] [Related]
26. Systemic and bronchodilator effects of inhaled rac-formoterol in subjects with chronic obstructive pulmonary disease: a dose-response study.
Whale CI; Sovani MP; Mortimer KJ; Harrison TW; Tattersfield AE
Br J Clin Pharmacol; 2008 Jun; 65(6):841-7. PubMed ID: 18394012
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD.
Reisner C; Pearle J; Kerwin EM; Rose ES; Darken P
Int J Chron Obstruct Pulmon Dis; 2018; 13():1965-1977. PubMed ID: 29950826
[TBL] [Abstract][Full Text] [Related]
28. Effects of formoterol (Oxis Turbuhaler) and ipratropium on exercise capacity in patients with COPD.
Liesker JJ; Van De Velde V; Meysman M; Vincken W; Wollmer P; Hansson L; Kerstjens HA; Qvint U; Pauwels RA
Respir Med; 2002 Aug; 96(8):559-66. PubMed ID: 12195835
[TBL] [Abstract][Full Text] [Related]
29. Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD.
Worth H; Förster K; Eriksson G; Nihlén U; Peterson S; Magnussen H
Respir Med; 2010 Oct; 104(10):1450-9. PubMed ID: 20692140
[TBL] [Abstract][Full Text] [Related]
30. Bronchodilator effects of indacaterol and formoterol in patients with COPD.
Beier J; Beeh KM; Brookman L; Peachey G; Hmissi A; Pascoe S
Pulm Pharmacol Ther; 2009 Dec; 22(6):492-6. PubMed ID: 19465142
[TBL] [Abstract][Full Text] [Related]
31. Assessment of a relative therapeutic index between inhaled formoterol and salbuterol in asthma patients.
Rosenborg J; Larsson P; Rott Z; Böcskei C; Poczi M; Juhász G
Eur J Clin Pharmacol; 2002 Jul; 58(4):S61-7. PubMed ID: 12214580
[TBL] [Abstract][Full Text] [Related]
32. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial.
Aalbers R; Ayres J; Backer V; Decramer M; Lier PA; Magyar P; Malolepszy J; Ruffin R; Sybrecht GW
Eur Respir J; 2002 May; 19(5):936-43. PubMed ID: 12030736
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra-long-acting β₂-adrenoceptor agonist, with formoterol in patients with asthma.
Bjermer L; Rosenborg J; Bengtsson T; Lötvall J
Ther Adv Respir Dis; 2013 Oct; 7(5):264-71. PubMed ID: 23907810
[TBL] [Abstract][Full Text] [Related]
34. Bronchodilator response to formoterol Turbuhaler in patients with COPD under regular treatment with formoterol Turbuhaler.
Cazzola M; Matera MG; D'Amato M; Califano C; Sanduzzi A; Vatrella A; D'Amato G
Pulm Pharmacol Ther; 2003; 16(2):105-9. PubMed ID: 12670779
[TBL] [Abstract][Full Text] [Related]
35. Dose-response curve to salbutamol during acute and chronic treatment with formoterol in COPD.
La Piana GE; Corda L; Bertella E; Montemurro LT; Pini L; Tantucci C
Int J Chron Obstruct Pulmon Dis; 2011; 6():399-405. PubMed ID: 21857779
[TBL] [Abstract][Full Text] [Related]
36. Faster onset of action of formoterol versus salmeterol in patients with chronic obstructive pulmonary disease: a multicenter, randomized study.
Cote C; Pearle JL; Sharafkhaneh A; Spangenthal S
Pulm Pharmacol Ther; 2009 Feb; 22(1):44-9. PubMed ID: 19071226
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of AZD3199 vs formoterol in COPD: a randomized, double-blind study.
Kuna P; Ivanov Y; Trofimov VI; Saito T; Beckman O; Bengtsson T; Jorup C; Maltais F
Respir Res; 2013 Jun; 14(1):64. PubMed ID: 23731768
[TBL] [Abstract][Full Text] [Related]
38. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
Lindberg A; Szalai Z; Pullerits T; Radeczky E
Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
[TBL] [Abstract][Full Text] [Related]
39. Budesonide/formoterol: in chronic obstructive pulmonary disease.
Reynolds NA; Perry CM; Keating GM
Drugs; 2004; 64(4):431-41; discussion 433-4. PubMed ID: 14969576
[TBL] [Abstract][Full Text] [Related]
40. Relief of dyspnoea by beta2-agonists after methacholine-induced bronchoconstriction.
van der Woude HJ; Postma DS; Politiek MJ; Winter TH; Aalbers R
Respir Med; 2004 Sep; 98(9):816-20. PubMed ID: 15338791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
